OREANDA-NEWS. Astellas Pharma Inc. (Tokyo：4503, President and CEO: Yoshihiko Hatanaka, hereinafter called “the Company”) announced that at the meeting of the Board of Directors held today, a resolution was adopted to acquire its own shares under Article 156 which is applicable in accordance with Article 165, paragraph 3 of the Companies Act.

Particulars

1. Reasons for the acquisition of own shares To improve capital efficiency and shareholder return.

2. Contents of acquisition

(1) Class of shares to be acquired: Common stock of the Company
(2) Total number of shares to be acquired: Up to 15 million shares (The percentage compared to the total number of shares outstanding: 0.69 %)
(3) Aggregate amount of acquisition cost: Up to 30 billion yen
(4) Period of acquisition: From August 3, 2015 to September 11, 2015

(Reference)

The status of treasury shares: Total number of shares outstanding: 2,173,198,302 shares Number of treasury shares*: 48,624,873 shares

*Total number of the treasury shares as of June 30, 2015 and the shares acquired from July 1, 2015 to July 10, 2015 based on the resolution of the Board of Directors meeting held on May 26th, 2015.